Business Alliance with Perspectum Ltd. Regarding Medical AI Diagnostic Imaging Products
-Contribution to Diagnosis and Treatment for Liver Disease-
May. 26. 2021
CLAIRVO TECHNOLOGIES, Inc. (hereinafter, "Clairvo"), a wholly owned subsidiary of Marubeni Corporation, and Perspectum Ltd. (hereinafter, "Perspectum"), a UK based company, have entered into a business alliance agreement (hereinafter, "this Alliance") for the purpose of commercializing medical AI diagnostic imaging products (hereinafter, “Product”) in the Japanese market.
This Product utilizes artificial intelligence (AI) technology to evaluate the condition of the patient’s liver from abdominal MRI images using a unique biomarker (*), and supports the diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic steatohepatitis (NASH). In terms of NASH, which can lead to liver cirrhosis and eventually liver cancer, the Product reduces the time, labor and physical burden of the diagnostic process as compared to the current liver biopsy diagnosis method in which the liver tissue is collected by needle insertion into the abdomen. The Product has already been approved as a medical device in the United States and Europe, and has been used in clinical practice.
According to The Japan Society of Hepatology, the number of patients with non-alcoholic fatty liver is increasing in Japan, and the prevalence of NAFLD is estimated to be about 30% of the population, while NASH is estimated to be about 2%.
Through this Alliance, Clairvo will proceed with the approval process for the Product with the relevant authorities in Japan, organize cooperation with research institutes and clinicians in departments such as gastroenterology and radiology, and provide the Product to medical institutions. Clarivo will continue its collaborations with domestic and overseas companies which develop medical AI diagnostic imaging products.
(*)biomarker : A physiological index that indicates the presence or absence of a certain disease and its progress.
|< About Perspectum >|
|Head Office||:||Oxford, United Kingdom|
|Business||:||Development and sales of diagnostic support solutions and services for patients with liver disease, diabetes, and cancer using AI technology|
|< About Clairvo >|
|Company||:||CLAIRVO TECHNOLOGIES, Inc.|
|Head Office||:||4-2, Ohtemachi 1-chome, Chiyoda-ku, Tokyo, Japan|
|Business||:||Development, manufacturing, sales/rental, import/export of medical devices/ services, other medical devices, and healthcare-related products to which AI and other advanced technologies are applied|
<Related Press Release＞
July 27th, 2020
Establishment of a New Subsidiary Company for AI Diagnosis Support Service to Medical Institutions
～Strengthening the Digital Health Business Domain～